Skip to main content
Erschienen in: Clinical Rheumatology 7/2007

01.07.2007 | Case Report

Durable remission of HIV-negative, Kaposi’s sarcoma herpes virus-associated multicentric Castleman disease in patient with rheumatoid arthritis treated with methotrexate

verfasst von: Samuel A. Jacobs, Nicholas Vidnovic, Hitendra Patel, Lorinda A. Soma, Yuan Chang, Noah Bass, Steven H. Swerdlow

Erschienen in: Clinical Rheumatology | Ausgabe 7/2007

Einloggen, um Zugang zu erhalten

Abstract

Multicentric Castleman disease (MCD) is a nonneoplastic lymphoproliferative disorder that has a poor prognosis. Optimal treatment is unknown. There are a few reported cases of MCD and rheumatoid arthritis. In this study, we report a patient with rheumatoid arthritis diagnosed with Kaposi’s sarcoma herpesvirus-(KSHV, human herpesvirus-8) associated MCD that showed expression of viral IL-6. Treatment with methotrexate (MTX) resulted in a complete remission of her disease lasting for 54+ months. Multiple studies have suggested that MCD and rheumatoid arthritis are associated with overexpression of the growth-promoting cytokine interleukin-6 (IL-6), and that MTX downregulates the production of this cytokine in vivo. As such, we suggest that the dramatic improvement in this patient’s disease is due to the immunomodulatory properties of MTX.
Literatur
1.
Zurück zum Zitat Castleman B, Towne VW (1954) Case records of the Massachusetts General Hospital: case no. 40231. N Engl J Med 250:1001–1005PubMedCrossRef Castleman B, Towne VW (1954) Case records of the Massachusetts General Hospital: case no. 40231. N Engl J Med 250:1001–1005PubMedCrossRef
2.
Zurück zum Zitat Castleman B, Iverson L, Menendez V (1956) Localized mediastinal lymph-node hyperplasia resembling thymoma. Cancer 9:822–830PubMedCrossRef Castleman B, Iverson L, Menendez V (1956) Localized mediastinal lymph-node hyperplasia resembling thymoma. Cancer 9:822–830PubMedCrossRef
3.
Zurück zum Zitat Keller AR, Hochhotzer L, Castleman B (1972) Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 29:670–683PubMedCrossRef Keller AR, Hochhotzer L, Castleman B (1972) Hyaline-vascular and plasma-cell types of giant lymph node hyperplasia of the mediastinum and other locations. Cancer 29:670–683PubMedCrossRef
4.
Zurück zum Zitat Frizzra G (1988) Castleman’s disease and related disorders. Semin Diagn Pathol 5:346–364 Frizzra G (1988) Castleman’s disease and related disorders. Semin Diagn Pathol 5:346–364
5.
Zurück zum Zitat Dupin N, Diss TL, Kellam P et al (2000) HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 95:1406–1412PubMed Dupin N, Diss TL, Kellam P et al (2000) HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 95:1406–1412PubMed
6.
Zurück zum Zitat Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J et al (1994) Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma (see comments). Science 266:1865–1869PubMedCrossRef Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J et al (1994) Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi’s sarcoma (see comments). Science 266:1865–1869PubMedCrossRef
7.
Zurück zum Zitat Soulier J, Grollet L, Oskenhendler E, Cacoub P et al (1995) Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood 86:126–180 Soulier J, Grollet L, Oskenhendler E, Cacoub P et al (1995) Kaposi’s sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman’s disease. Blood 86:126–180
8.
Zurück zum Zitat Suda T, Katano H, Delso G et al (2001) HHV-8 infection status of AIDS-unrelated and AIDS-associated multicentric Castleman’s disease. Pathol Int 51:671PubMedCrossRef Suda T, Katano H, Delso G et al (2001) HHV-8 infection status of AIDS-unrelated and AIDS-associated multicentric Castleman’s disease. Pathol Int 51:671PubMedCrossRef
9.
Zurück zum Zitat Katano H, Sata T (1999) An attractive relation of human herpesvirus-8 with multicentric Castleman’s disease. Intern Med 38:221–222PubMed Katano H, Sata T (1999) An attractive relation of human herpesvirus-8 with multicentric Castleman’s disease. Intern Med 38:221–222PubMed
10.
Zurück zum Zitat DeJong R, Baatenburg R, Kluin PM et al (2003) Sustained high levels of serum HHV-8 DNA years before multicentric Castleman’s disease despite full suppression of HIV with highly active antiretroviral therapy. AIDS 17:1407–1408CrossRef DeJong R, Baatenburg R, Kluin PM et al (2003) Sustained high levels of serum HHV-8 DNA years before multicentric Castleman’s disease despite full suppression of HIV with highly active antiretroviral therapy. AIDS 17:1407–1408CrossRef
11.
Zurück zum Zitat Hsu SM, Waldron JA, Xie SS, Barlogie B (1993) Expression of interleukin-6 in Castleman’s disease. Hum Pathol 24:833–839PubMedCrossRef Hsu SM, Waldron JA, Xie SS, Barlogie B (1993) Expression of interleukin-6 in Castleman’s disease. Hum Pathol 24:833–839PubMedCrossRef
12.
Zurück zum Zitat Brandt SJ, Bodine DM, Dunbar CE, Nienhuis AW (1990) Dysregulated interleukin 6 expression produces a syndrome resembling Castleman’s disease in mice. J Clin Invest 86:592PubMedCrossRef Brandt SJ, Bodine DM, Dunbar CE, Nienhuis AW (1990) Dysregulated interleukin 6 expression produces a syndrome resembling Castleman’s disease in mice. J Clin Invest 86:592PubMedCrossRef
13.
Zurück zum Zitat Dupin N, Fisher C, Kellam P, Ariad S et al (1996) Distribution of human herpesvirus-8 latently infected cells in Kaposi’s sarcoma, multicentric Castleman’s disease, and primary effusion lymphoma. Proc Natl Acad Sci USA 4546–4551 Dupin N, Fisher C, Kellam P, Ariad S et al (1996) Distribution of human herpesvirus-8 latently infected cells in Kaposi’s sarcoma, multicentric Castleman’s disease, and primary effusion lymphoma. Proc Natl Acad Sci USA 4546–4551
14.
Zurück zum Zitat Parravicini C, Corbellino M, Paulli M et al (1997) Expression of a virus-derived cytokine, KSHV vIL-6, in HIV-seronegative Castleman’s disease. Am J Pathol 151:1517–1522PubMed Parravicini C, Corbellino M, Paulli M et al (1997) Expression of a virus-derived cytokine, KSHV vIL-6, in HIV-seronegative Castleman’s disease. Am J Pathol 151:1517–1522PubMed
15.
Zurück zum Zitat Herrada j,Cabanillas,F,Rice L et al (1988) The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med 128(8):652–657 Herrada j,Cabanillas,F,Rice L et al (1988) The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med 128(8):652–657
16.
Zurück zum Zitat Marcelin AG, Aaron L, Mateus C et al (2003) Rituximab therapy for HIV-associated Castleman dsease. Blood 102(8):2786–2788PubMedCrossRef Marcelin AG, Aaron L, Mateus C et al (2003) Rituximab therapy for HIV-associated Castleman dsease. Blood 102(8):2786–2788PubMedCrossRef
17.
Zurück zum Zitat Corbellino M, Bestetti G, Scalamogna C et al (2001) Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood 98:3473–3475PubMedCrossRef Corbellino M, Bestetti G, Scalamogna C et al (2001) Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood 98:3473–3475PubMedCrossRef
18.
Zurück zum Zitat Jung CP, Emmerich B, Goebel FD, Bogner JR (2004) Successful treatment of a patient with HIV-associated multicentric Castleman disease (MCD) with thalidomide. Am J Hematol 75:176–177PubMedCrossRef Jung CP, Emmerich B, Goebel FD, Bogner JR (2004) Successful treatment of a patient with HIV-associated multicentric Castleman disease (MCD) with thalidomide. Am J Hematol 75:176–177PubMedCrossRef
19.
Zurück zum Zitat Kumari P, Schechter G, Saini N, Benator D (2000) Successful treatment of human immunodeficiency virus related Castleman’s disease with interferon. Clin Infect Dis 31:602PubMedCrossRef Kumari P, Schechter G, Saini N, Benator D (2000) Successful treatment of human immunodeficiency virus related Castleman’s disease with interferon. Clin Infect Dis 31:602PubMedCrossRef
20.
Zurück zum Zitat Gholam D, Vantelon JM, Al-Jijakli A, Bourhis JH (2003) A case of multicentric Castleman’s disease associated with advanced systemic amyloidosis treated with chemotherapy and anti-CD20 monoclonal antibody. Ann Hematol 82:766–768;203PubMedCrossRef Gholam D, Vantelon JM, Al-Jijakli A, Bourhis JH (2003) A case of multicentric Castleman’s disease associated with advanced systemic amyloidosis treated with chemotherapy and anti-CD20 monoclonal antibody. Ann Hematol 82:766–768;203PubMedCrossRef
21.
Zurück zum Zitat Gerards AH, deLathouder S, DeGroot ER et al (2003) Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology 42:1189–1196PubMedCrossRef Gerards AH, deLathouder S, DeGroot ER et al (2003) Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology 42:1189–1196PubMedCrossRef
22.
Zurück zum Zitat Aggarwal A, Misra R (2003) Methotrexate inhibits interleukin-6 production in patients with juvenile rheumatoid arthritis. Rheumatol Int 23:134–137PubMed Aggarwal A, Misra R (2003) Methotrexate inhibits interleukin-6 production in patients with juvenile rheumatoid arthritis. Rheumatol Int 23:134–137PubMed
23.
Zurück zum Zitat Nishimoto N, Sasai M, Shima Y et al (2000) Improvement in Castleman’s disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 95(1):56–61PubMed Nishimoto N, Sasai M, Shima Y et al (2000) Improvement in Castleman’s disease by humanized anti-interleukin-6 receptor antibody therapy. Blood 95(1):56–61PubMed
24.
Zurück zum Zitat Osborne J, Moore PS, Chang Y (1999) KSHV-encoded viral IL-6 activates multiple human IL-6 signaling pathways. Hum Immunol 60(10):921–927PubMedCrossRef Osborne J, Moore PS, Chang Y (1999) KSHV-encoded viral IL-6 activates multiple human IL-6 signaling pathways. Hum Immunol 60(10):921–927PubMedCrossRef
25.
Zurück zum Zitat Curreli F, Cerimele F, Muralindhar S et al (2002) Transcriptional downregulation of ORF50/Rta by methotrexate inhibits the switch of Kaposi’s sarcoma-associated herpesvirus/human herpesvirus 8 from latency to lytic reproduction. J Virol 76:5208–5219PubMedCrossRef Curreli F, Cerimele F, Muralindhar S et al (2002) Transcriptional downregulation of ORF50/Rta by methotrexate inhibits the switch of Kaposi’s sarcoma-associated herpesvirus/human herpesvirus 8 from latency to lytic reproduction. J Virol 76:5208–5219PubMedCrossRef
Metadaten
Titel
Durable remission of HIV-negative, Kaposi’s sarcoma herpes virus-associated multicentric Castleman disease in patient with rheumatoid arthritis treated with methotrexate
verfasst von
Samuel A. Jacobs
Nicholas Vidnovic
Hitendra Patel
Lorinda A. Soma
Yuan Chang
Noah Bass
Steven H. Swerdlow
Publikationsdatum
01.07.2007
Verlag
Springer-Verlag
Erschienen in
Clinical Rheumatology / Ausgabe 7/2007
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-006-0272-8

Weitere Artikel der Ausgabe 7/2007

Clinical Rheumatology 7/2007 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Semaglutid bei Herzinsuffizienz: Wie erklärt sich die Wirksamkeit?

17.05.2024 Herzinsuffizienz Nachrichten

Bei adipösen Patienten mit Herzinsuffizienz des HFpEF-Phänotyps ist Semaglutid von symptomatischem Nutzen. Resultiert dieser Benefit allein aus der Gewichtsreduktion oder auch aus spezifischen Effekten auf die Herzinsuffizienz-Pathogenese? Eine neue Analyse gibt Aufschluss.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.